TRODELVY Clinical Data: PFS

Superior PFS vs chemotherapy¹

TRODELVY helped patients experience significantly longer PFS vs single-agent chemotherapy*¹

*Assessed by independent central review in the ITT population. The PFS improvement in the primary analysis population (median PFS: 5.6 months vs 1.7 months; HR: 0.41; P<.0001) was consistent with the ITT population. The primary analysis population consisted of patients without present or prior history of brain metastases at baseline (n=468). The ITT population consisted of patients with or without brain metastases at baseline (N=529). ITT population final database lock 25 February 2021. ^1†TRODELVY demonstrated a 57% reduction in the risk of disease progression or death.¹

ABBREVIATIONS:

CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; NE, not estimable; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; TNBC, triple-negative breast cancer.

REFERENCES:

TRODELVY (sacituzumab govitecan) Summary of Product Characteristics. February 2023.
Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.

TRODELVY 200mg

Clinical Data

Superior PFS vs chemotherapy¹

TRODELVY helped patients experience significantly longer PFS vs single-agent chemotherapy*¹

ABBREVIATIONS:

REFERENCES:

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

ΛΙΑΝΙΚΗ ΤΙΜΗ

Superior PFS vs chemotherapy1

TRODELVY helped patients experience significantly longer PFS vs single-agent chemotherapy*1

PFS benefit vs chemotherapy was consistently demonstrated across all patient subgroups1,2

Median PFS by subgroup*2

ABBREVIATIONS:

REFERENCES:

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

ΛΙΑΝΙΚΗ ΤΙΜΗ

Superior PFS vs chemotherapy¹

TRODELVY helped patients experience significantly longer PFS vs single-agent chemotherapy*¹

PFS benefit vs chemotherapy was consistently demonstrated across all patient subgroups^1,2

Median PFS by subgroup*²